Brigatinib (BRG) in crizotinib (CRZ)-refractory ALK+ non–small cell lung cancer (NSCLC): Efficacy updates and exploratory analysis of CNS ORR and overall ORR by baseline (BL) brain lesion status

Rudolf Maria Huber, Dong-Wan Kim, Myung-Ju Ahn, Corey J Langer, Marcello Tiseo, Howard West, Harry J M Groen, Karen L Reckamp, Maximilian J Hochmair, Natasha B Leighl, Karin Holmskov Hansen, Scott N Gettinger, Luis G Paz-Ares, Edward S Kim, Egbert F Smit, Sang-We Kim, William Reichmann, David Kerstein, D Ross Camidge

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

OriginalsprogEngelsk
TidsskriftJournal of Clinical Oncology
Vol/bind36
Udgave nummer15 Suppl.
Sider (fra-til)9061
Antal sider1
ISSN0732-183X
DOI
StatusUdgivet - 2018
Begivenhed2018 ASCO Annual Meeting: Delivering discoveries: Expanding the reach of precision medicine - McCormick Place, Chicago , USA
Varighed: 1. jun. 20185. jun. 2018
https://am.asco.org

Konference

Konference2018 ASCO Annual Meeting
LokationMcCormick Place
LandUSA
ByChicago
Periode01/06/201805/06/2018
Internetadresse

Citationsformater

Huber, R. M., Kim, D-W., Ahn, M-J., Langer, C. J., Tiseo, M., West, H., Groen, H. J. M., Reckamp, K. L., Hochmair, M. J., Leighl, N. B., Holmskov Hansen, K., Gettinger, S. N., Paz-Ares, L. G., Kim, E. S., Smit, E. F., Kim, S-W., Reichmann, W., Kerstein, D., & Camidge, D. R. (2018). Brigatinib (BRG) in crizotinib (CRZ)-refractory ALK+ non–small cell lung cancer (NSCLC): Efficacy updates and exploratory analysis of CNS ORR and overall ORR by baseline (BL) brain lesion status. Journal of Clinical Oncology, 36(15 Suppl.), 9061. https://doi.org/10.1200/JCO.2018.36.15_suppl.9061